Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345645 | 1.00 | RAB9A (0.56) | RAB9ALMNA | |
| SCHEMBL22345646 | 1.00 | RAB9A (0.56) | RAB9ALMNA | |
| SCHEMBL22345647 | 0.89 | RAB9A (0.42) | RAB9A | |
| SCHEMBL22345644 | 0.89 | RAB9A (0.42) | RAB9A | |
| SCHEMBL22360567 | 0.88 | RAB9A (0.44) | RAB9A | |
| SCHEMBL22360516 | 0.88 | RAB9A (0.44) | RAB9A | |
| SCHEMBL22345774 | 0.82 | RAB9A (0.33) | RAB9A | |
| SCHEMBL28666673 | 0.82 | RAB9A (0.33) | RAB9A | |
| SCHEMBL22345654 | 0.82 | RAB9A (0.33) | RAB9A | |
| SCHEMBL28665048 | 0.82 | RAB9A (0.33) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248960-A2 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230174570-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2023-06-08 | — | — | US | disclosed |
| EP-4103579-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2022-12-21 | — | — | EP | disclosed |
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2022-06-09 | — | — | US | disclosed |
| EP-3924361-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021161206-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020165741-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, HSD17B7 | RAB9A 1409/4885LMNA 4342/4885 |
| US-20230174570-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, CYP4A11 | RAB9A 1731/4885LMNA 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.